Sign In
Buy IVVD
$1.10
-0.0400 (-3.51%)
At Close: Jun 03, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:01am, Wednesday, 03'rd Jun 2026
NEW HAVEN, Conn., June 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on June 1, 2026, Invivyd granted 17 newly hired non-executive employees options to purchase an agg
NEW HAVEN, Conn., June 01, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the completion of enrollment in the DECLARATION trial evaluating VYD2311, an investigational monoclonal
Invivyd to Participate in Upcoming Investor Events
07:01am, Wednesday, 27'th May 2026
NEW HAVEN, Conn., May 27, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will participate in upcoming investor events in June:
Invivyd, Inc. (IVVD) Q1 2026 Earnings Call Transcript
12:31pm, Thursday, 14'th May 2026
Invivyd, Inc. (IVVD) Q1 2026 Earnings Call Transcript
Invivyd Q1 Earnings Call Highlights
12:16pm, Thursday, 14'th May 2026
Invivyd NASDAQ: IVVD said its first quarter of 2026 was marked by continued progress in its pivotal COVID-19 antibody program, year-over-year growth for PEMGARDA and elevated clinical spending tied to
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
09:16am, Thursday, 14'th May 2026
Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.14 per share a year ago.
Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights
07:01am, Thursday, 14'th May 2026
Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 million Invivyd in vitro data showed continued neutra
Invivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody adintrevimab from the EVADE study, demonstrating minimal tolerability issues Results allow for compar
Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026
07:01am, Thursday, 07'th May 2026
NEW HAVEN, Conn., May 07, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced th
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:01am, Tuesday, 05'th May 2026
NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on May 1, 2026, Invivyd granted 17 newly hired non-executive employees options to purchase an aggre
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit
07:01am, Monday, 20'th Apr 2026
Elia to speak at the premier gathering of policy makers, industry leaders, and health experts between 11:30 AM ET – 12:00 PM ET on April 21 Event to be live streamed between 9:00 AM – 1:00 PM ET N
Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Monoclonal Antibody Candidate Transcript
Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program
10:07am, Thursday, 09'th Apr 2026
The company said its Phase 3 DECLARATION trial evaluating VYD2311 for COVID-19 prevention has reached a key interim milestone.
NEW HAVEN, Conn., April 09, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced progress in its REVOLUTION clinical program for VYD2311, a novel monoclonal antibody investigational c
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:01am, Monday, 06'th Apr 2026
NEW HAVEN, Conn., April 06, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on April 1, 2026, Invivyd granted 16 newly hired non-executive employees options to purchase an a
